%0 Journal Article %1 Jain.2009 %A Jain, R. K. %A Duda, D. G. %A Willett, C. G. %A Sahani, D. V. %A Zhu, A. X. %A Loeffler, J. S. %A Batchelor, T. T. %A Sorensen, A. G. %D 2009 %J Nat.Rev.Clin.Oncol. %K & A Angiogenesis Biological Drug Endothelial Factor Growth Humans Hypertension Inhibitors Markers Neoplasm Neoplasms Neovascularization Pathologic Research Resistance Tumor Vascular antagonists blood control inhibitors metabolism prevention response supply therapeutic therapy use %N 6 %P 327-338 %T Biomarkers of response and resistance to antiangiogenic therapy %U PM:19483739 %V 6 %X No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of th

@article{Jain.2009, abstract = {No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of th}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Jain, R. K. and Duda, D. G. and Willett, C. G. and Sahani, D. V. and Zhu, A. X. and Loeffler, J. S. and Batchelor, T. T. and Sorensen, A. G.}, biburl = {https://www.bibsonomy.org/bibtex/220e4b4a8b9dbb425000ccf7379126992/kanefendt}, interhash = {6ea4790771826bc9670799a7b3db6fbd}, intrahash = {20e4b4a8b9dbb425000ccf7379126992}, journal = {Nat.Rev.Clin.Oncol.}, keywords = {& A Angiogenesis Biological Drug Endothelial Factor Growth Humans Hypertension Inhibitors Markers Neoplasm Neoplasms Neovascularization Pathologic Research Resistance Tumor Vascular antagonists blood control inhibitors metabolism prevention response supply therapeutic therapy use}, number = 6, pages = {327-338}, timestamp = {2010-02-05T11:28:51.000+0100}, title = {Biomarkers of response and resistance to antiangiogenic therapy}, url = {PM:19483739}, volume = 6, year = 2009 }